Article

CAR T-Cell Therapy Offers Hope in DLBCL

Author(s):

Peter Borchmann, M.D.

CAR-T cell therapy is generating excitement for the treatment of diffuse large B-cell lymphoma, according to an update from the JULIET trial.

Findings from the JULIET trial are generating hope and excitement for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, according to Peter Borchmann, M.D., professor at the University Hospital of Cologne in Germany.

The phase 2 trial is investigating the CAR-T cell therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory DLBCL. Borchmann explained that at the median follow-up of 14 months, the researchers are still seeing a high amount of patients who are responding to treatment. While longer observation is needed, he said that the findings from this study are generating hope that more patients with DLBCL can obtain and remain in remission.

Related Videos
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Related Content
Illustration of blood cells.
March 17th 2025

Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia

Ryan Scott
Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.
Mike Peters in the hospital holding a black guitar and chemo pole
June 1st 2023

Mike Peters of The Alarm Faces Cancer With Rock Optimism on New Album

Alex Biese
‘Forwards,’ the new album by Mike Peters and the Alarm, was written while he was hospitalized for treatment of chronic lymphocyte leukemia and pneumonia.
Image of Dr. Fakih.
February 27th 2025

ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer

Dr. Marwan Fakih
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.
Dr. Dawn Mussallem in a bright yellow shirt and pink hat, both with breast cancer ribbons on it, showing off her medal at the finish line of The DONNA Foundaton marathon | Photo credit: The DONNA Foundation
May 18th 2023

Doctor, Cancer Survivor and Marathoner Goes the Distance for Her Patients: ‘Now I Can Just Give’

Alex Biese
Dr. Dawn Mussallem of the Mayo Clinic tells CURE®’s “Cancer Horizons” podcast about how surviving stage 4 non-Hodgkin’s lymphoma and being a heart transplant recipient helps her connect with her patients.
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
February 21st 2025

How Patients With Cancer Can Avoid Counterfeit Therapeutics Online

Dr. Megan Menon
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
Dr. Robert Jones is a professor of Clinical Cancer Research at The University of Glasgow School of Cancer Sciences, in Scotland.
February 15th 2025

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

Dr. Robert Jones
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.